Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019

Jin, Yujiao; Wang, Miaochan; Zuo, Zhongbao; Cheng, Fan; Ye, Fei; Cai, Zhen; Ying, Wang; Cui, Huaizhong; Pan, Ke-nü; Xu, Aiqiang

doi:10.1016/j.ijid.2020.03.065

Cited by 280 publications

(320 citation statements)

References 10 publications

Supporting

Mentioning

269

Contrasting

Unclassified

Order By: Relevance

“…1A), while that of IgG remained stable at above 400 AU/mL after Day 13 ( Fig.1B). Similar dynamic changes were also reported by another study 7 . The timing when the median titers of IgM and IgG exceeded the manufacturer's cutoff value (10 AU/mL) were Day13-14 and Day9-10, respectively, which might beare similar to those for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) 8 and slightly earlier than those for Middle East respiratory syndrome coronavirus (MERS-CoV) 9,10 .…”

Section: Discussionsupporting

confidence: 91%

Time course of the sensitivity and specificity of serum anti-SARS-CoV-2 IgM and IgG antibodies for the diagnosis of symptomatic COVID-19 in Japan

Nakano

Kurano

Morita

et al. 2020

Preprint

View full text Add to dashboard Cite

The accurate and prompt diagnosis of SARS-CoV-2 infection is required for the control and treatment of the coronavirus infection disease 2019 (COVID-19). In this study, we aimed to investigate the time courses of the anti-severe acute corona respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and IgG titers and to evaluate the sensitivity and specificity of such tests according to the specific day after the onset of COVID-19 among a patient population in Japan. We measured the titers of SARS-CoV-2 IgM and IgG in sera from 100 subjects, including 26 symptomatic COVID-19 patients, using chemiluminescent immunoassay (CLIA) methods utilizing magnetic beads coated with SARS-CoV-2 nucleocapsid protein and spike protein. The results of a ROC analysis suggested the possibility that the cutoff values in Japan might be lower than the manufacturer’s reported cutoff (10 AU/mL): 1 AU/mL for IgM and 5 AU/mL for IgG. The sensitivity of the test before Day 8 after symptom onset was less than 50%; at Days 9-10, however, we obtained a much higher sensitivity of 81.8% for both IgM and IgG. At 15 days or later after symptom onset, the SARS-CoV-2 IgG test had a sensitivity of 100%. These results suggest that if the number of days since disease onset is taken into consideration, these antibody tests could be very useful for the diagnosis of COVID-19 and similar diseases.

show abstract

Section: Discussionsupporting

confidence: 91%

Time course of the sensitivity and specificity of serum anti-SARS-CoV-2 IgM and IgG antibodies for the diagnosis of symptomatic COVID-19 in Japan

Nakano

Kurano

Morita

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Studies on SARS-CoV-1 showed that most patients seroconverted after infection but this was delayed (17-21 days) compared to a typical time course for seroconversion with other 325 respiratory viruses 30,31 . Several studies demonstrate seroconversion of IgG antibodies against the spike protein 1-3 weeks after infection with SARS-CoV-2 [32][33][34][35][36] 38 . Similarly, the median time for seroconversion to IgG in hospitalized patients was found to be 14 days in a study of 173 patients in China, with some taking up to 1 month to generate antibody detectable in a commercial ELISA test 39 .…”

Section: The Relationship Between Seroprevalence and Sars-cov-2 Exposmentioning

confidence: 99%

Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020

Thompson

Grayson

Paton

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. The extent of spread of SARS coronavirus 2 (SARS-CoV-2) in the UK and elsewhere is unknown because typically only symptomatic individuals are diagnosed. We performed a serological study of recent blood donors in Scotland to detect antibodies to SARS-CoV-2 as a marker of past infection. Methods. A pseudotyped SARS-CoV-2 virus microneutralisation assay was used to detect neutralising antibodies to SARS-CoV-2. The study group comprised samples from 1000 blood donors collected in Scotland during March, 2020. Controls were collected from 100 donors in Scotland during 2019. Findings. All samples collected on the 17th March, 2020 (n=500) were negative in the pseudotyped SARS-CoV-2 virus microneutralisation assay. Neutralising antibodies were detected in 5 of the 500 samples collected 21st to 23rd March; one further sample was reactive in an anti-spike ELISA. Interpretation. Although we cannot use the rise in numbers seropositive to infer the contemporary seroprevalence or the growth rate of the epidemic, we note that they are consistent with frequency of reported diagnosed infections and SARS-CoV-2-associated deaths reported in that time period in Scotland, given that seroconversion takes up to 2-3 weeks. It should also be noted that blood donors are not representative of the general population; in particular, those with a history of recent respiratory infections are deferred. Finally, it is unknown what proportion of infected individuals seroconvert and become reactive in the assays used. Serial follow up studies are needed to track infection and seroconversion in this and other similar populations However, these data indicate that sero-surveys of blood banks can serve as a useful tool for tracking the emergence and progression of an epidemic like the current SARS-CoV-2 outbreak.

show abstract

“…11 The aim of the this study was to assess the diagnostic performance of a novel fully automated CLIA for the quantitative detection of anti-SARS-CoV-2 IgM and IgG antibodies. [12][13][14][15] However, it is unclear which antibodies are optimally effective in the scenario of COVID-19 and which of them are neutralizing. There is also uncertainty as to which antibody isotype (IgM, IgG or IgA) (single or combined) is the best choice in these different contexts.…”

mentioning

confidence: 99%

Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience

Infantino

Grossi

Lari

et al. 2020

Journal of Medical Virology

146

124

View full text Add to dashboard Cite

A pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading throughout the world. Though molecular diagnostic tests are the gold standard for COVID-19, serological testing is emerging as a potential surveillance tool, in addition to its complementary role in COVID-19 diagnostics. Indubitably quantitative serological testing provides greater advantages than qualitative tests but today there is still little known about serological diagnostics and what the most appropriate role quantitative tests might play. Sixty-one COVID-19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti-SARS CoV-2 antibodies IgM and IgG. All COVID-19 patients were hospitalized in San Giovanni di Dio Hospital (Florence, Italy) and had a positive oro/nasopharyngeal swab reversetranscription polymerase chain reaction result. The highest sensitivity with a very good specificity performance was reached at a cutoff value of 10.0 AU/mL for IgM and of 7.1 for IgG antibodies, hence near to the manufacturer's cutoff values of 10 AU/mL for both isotypes. The receiver operating characteristic curves showed area under the curve values of 0.918 and 0.980 for anti-SARS CoV-2 antibodies IgM and IgG, respectively. iFlash1800 CLIA analyzer has shown highly accurate results for the anti-SARS-CoV-2 antibodies profile and can be considered an excellent tool for COVID-19 diagnostics.

show abstract

Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019

Cited by 280 publications

References 10 publications

Time course of the sensitivity and specificity of serum anti-SARS-CoV-2 IgM and IgG antibodies for the diagnosis of symptomatic COVID-19 in Japan

Time course of the sensitivity and specificity of serum anti-SARS-CoV-2 IgM and IgG antibodies for the diagnosis of symptomatic COVID-19 in Japan

Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020

Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience

Contact Info

Product

Resources

About